Poland· PL-100314706
Salofalk
A mesalazine product containing mesalazinum, registered in Poland by Dr. Falk Pharma GmbH. The same ATC class is registered in 17 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Mesalazine is registered in 17 of 19 countries.
Countries holding a registration under ATC A07EC02 (mesalazine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 9 of them publish a price we can compare per daily dose
Mesalazine · ATC A07EC02
17 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Sweden
- Switzerlandprice
- United Kingdom
Price per daily dose
What a daily dose of mesalazine costs, country by country.
Normalised to the WHO defined daily dose (1.5 g), the median price runs from $1.00 in Italy to $2.13 in Switzerland — a ×2.1 gap.
- 3 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Mesalazine · price per daily dose (1.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$2.13
- FR France$1.06
- IT Italy$1.00
The record
At a glance
URPL (Poland)- Active substance
- Mesalazinum
- Manufacturer
- Dr. Falk Pharma GmbH
- Country
- Poland (PL)
- ATC code
- A07EC02
- ATC class
- Mesalazine
- Defined daily dose
- 1.5 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 10
- gtin05909991134976
- gtin05909991134983
- gtin05909991134990
- gtin05909991135003
- gtin05909991135010
- gtin05909991135027
- gtin05909991135034
- gtin05909991135041
- gtin05909991135058
- gtin05909991135065
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
333 interactions on record for mesalazine.
Graded by severity as the source publishes them — 15 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Mesalazine · interactions on record
333 records
- 15 severe
- 95 moderate
- 223 info
Most severe, free to view
- CidofovirJ05AB12severe
- Humane Immunglobuline, unspezifisch, extravaskulärJ06BA01severe
- Humane Immunglobuline, unspezifisch, intravaskulärJ06BA02severe
- SirolimusL01EG04severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Mesalazine in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaSALOFALKDr. Falk Pharma GmbH, Freiburg
- NetherlandsSalofalk 1,5 g Granu-Stix, granulaat met verlengde afgifteMedcor Pharmaceuticals B.V.
- SpainSALOFALK 1,5 g GRANULADO DE LIBERACION PROLONGADADr. Falk Pharma Gmbh
- FinlandSalofalkDr. Falk Pharma GmbH
- FranceOSPERZO 1,5 g, granulés à libération prolongéeFALK PHARMA
- IrelandSalofalk 1.5g prolonged-release granulesDr. Falk Pharma GmbH
- NorwaySalofalkDr. Falk Pharma GmbH
- BelgiumColitofalk 1.5 gDr. Falk Pharma
Authorised across Europe · EMA
The same active substance is authorised in 29 EEA countries. Names it is sold under:
- Austria · Azzavix, Claversal
- Belgium · Asamovon, Claversal
- Bulgaria · Salofalk – Салофалк, Пентаза
- Cyprus · Asacol, Mecolzine
- Czechia · Asacol, Asacol Enema
- Germany · Asacol, Claversal
- Denmark · Asacol, Mesalazin Orion
- Estonia · Asacol, Pentasa
- Spain · Asacol, Azzavix
- Finland · Asacol, Asacol 1 G
- France · Fivasa, Mazalvix
- United Kingdom (Northern Ireland) · Asacol, Mesalazine
- Greece · Asacol, Asalazin
- Croatia · Pentasa, Salofalk
- Hungary · Pentasa, Salofalk
- Ireland · Asacolon, Galtasa
- Iceland · Asacol, Pentasa
- Italy · Argonal, Asacol
- Lithuania · Asacol, Pentasa
- Luxembourg · Claversal, Claversal Foam
- Latvia · Asacol, Pentasa
- Malta · Mecolzine, Mezavant Xl
- Netherlands · Asacol, Azzavix
- Norway · Asacol, Mesalazin Orion
- Portugal · Asacol, Azzavix
- Romania · Mesalazina Alfasigma, Pentasa
- Sweden · Asacol, Mesalazin Orion
- Slovenia · Asacol, Asacol®
- Slovakia · Pentasa, Pentasa Sachet
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ce1b5a71-976f-49ac-8ef0-6cb1a586cceb GET /v1/drugs/ce1b5a71-976f-49ac-8ef0-6cb1a586cceb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Granulat dojelitowy o przedłużonym uwalnianiu",
"source": "urpl",
"strength": "1,5 g",
"packaging": "05909991134976 ¦ Rp ¦ 90818\n20 sasz. 2,79 g granulatu\n05909991134983 ¦ Rp ¦ 90819\n30 sasz. 2,79 g granulatu\n05909991134990 ¦ Rp ¦ 90820\n35 sasz. 2,79 g granulatu\n05909991135003 ¦ Rp ¦ 90821\n45 sasz. 2,79 g granulatu\n05909991135010 ¦ Rp ¦ 90822\n50 sasz. 2,79 g granulatu\n05909991135027 ¦ Rp ¦ 90823\n60 sasz. 2,79 g granulatu\n05909991135034 ¦ Rp ¦ 90824\n70 sasz. 2,79 g granulatu\n05909991135041 ¦ Rp ¦ 90825\n90 sasz. 2,79 g granulatu\n05909991135058 ¦ Rp ¦ 90826\n100 sasz. 2,79 g granulatu\n05909991135065 ¦ Rp ¦ 90827\n150 sasz. 2,79 g granulatu",
"substance": "Mesalazinum 1.5 g",
"common_name": "Mesalazinum",
"pl_product_id": "100314706",
"pozwolenie_nr": "21830",
"auth_procedure": "MRP",
"authorisation_validity": "Bezterminowe"
}See everything about mesalazine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.